A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
NCT01519804
Completed
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC). Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and platinum (carboplatin/cisplatin) iv on Day 1 of e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2016
Locations: Not set, Huntsville, Alabama +68 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +132 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
NCT01242605
Completed
The objective of this study is to establish the recommended dose of selumetinib, a novel MEK inhibitor for use in combination with gemcitabine and cisplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2016
Locations: Hammersmith Hospital, London, Not set +2 locations
Conditions: Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Neoplasms
Register for Updates
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
NCT00859339
Terminated
This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: University of Florida, Gainesville, Florida +4 locations
Conditions: Transitional Cell Carcinoma of the Bladder
Register for Updates
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT01697072
Terminated
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/18/2016
Locations: Research Site, Tucson, Arizona +190 locations
Conditions: Gastric Cancer
Register for Updates
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
NCT01161498
Terminated
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2016
Locations: Investigative Clinical Research of Indiana, Indianapolis, Indiana +5 locations
Conditions: Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT01185847
Completed
This open label, 2-part study will evaluate the safety and efficacy of RO5083945 in combination with standard chemotherapy in patients with advanced or recurrent non-small cell lung cancer who have not received prior chemotherapy. In Part 1 patients will receive RO5083945 intravenously and standard chemotherapy (cisplatin plus either gemcitabine or pemetrexed) for up to 6 cycles of 3 weeks and then RO5083945 until disease progression. In Part 2 patients will be randomized to receive either RO508... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/31/2015
Locations: Not set, Charleroi, Not set +31 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
NCT02051868
Unknown
Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease. The aim of this phase II study is compare two well known and largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will set a standard of care for this disease and provide useful information for future Phase III trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2015
Locations: Laura Gagnon, Boston, Massachusetts +2 locations
Conditions: Squamous Cell Carcinoma of the Anus
Register for Updates
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003636
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy before surgery is more effective than chemotherapy after surgery in treating ovarian, peritoneal, or fallopian tube cancer. PURPOSE: This randomized phase III trial is studying chemotherapy given before surgery to see how well it works compared to chemotherapy given after su... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
08/04/2015
Locations: Hospital de Clinicas "Jose De San Martin", Buenos Aires, Not set +64 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
NCT00387127
Completed
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo. The study is designed to evaluate and compare the two treatment groups with respect to complete response rate at 6 months following chemoradiation completion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2015
Locations: GSK Investigational Site, Minneapolis, Minnesota +29 locations
Conditions: Neoplasms, Head and Neck
Register for Updates
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
NCT01714037
Terminated
Part A of this study will investigate the Maximum Tolerated Dose of Debio 0932 in combination with standard of care chemotherapy for the first- and second-line treatment of advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2015
Locations: Centre GF Leclerc, Dijon, Not set +7 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT00449033
Completed
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2015
Locations: Not set, Innsbruck, Not set +120 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates